Q3 2024 |
63 |
$1.7B |
+$43.8M |
-$155M |
-$111M |
KRYS, NRIX, FOLD, IMNM, KYMR
|
13F-HR |
11/14/2024, 04:15 PM |
Q2 2024 |
63 |
$1.65B |
+$47M |
-$529M |
-$482M |
KRYS, FOLD, NRIX, STOK, IMNM
|
13F-HR |
8/14/2024, 04:16 PM |
Q1 2024 |
77 |
$2.72B |
+$468M |
-$882M |
-$414M |
KRYS, FOLD, IMNM, SRRK, FATE
|
13F-HR |
5/15/2024, 04:50 PM |
Q4 2023 |
70 |
$2.8B |
+$465M |
-$319M |
+$145M |
IMGN, KRYS, FOLD, SRRK, RYZB
|
13F-HR |
2/14/2024, 04:16 PM |
Q3 2023 |
68 |
$2.1B |
+$137M |
-$372M |
-$235M |
IMGN, KRYS, FOLD, AKRO, AUGX
|
13F-HR |
11/14/2023, 04:15 PM |
Q2 2023 |
72 |
$2.61B |
+$487M |
-$443M |
+$43.5M |
IMGN, KRYS, FOLD, REPL, AKRO
|
13F-HR |
8/14/2023, 04:15 PM |
Q1 2023 |
76 |
$2.3B |
+$383M |
-$273M |
+$111M |
FOLD, KRYS, ISEE, DCPH, AKRO
|
13F-HR |
5/15/2023, 04:15 PM |
Q4 2022 |
69 |
$2.44B |
+$290M |
-$327M |
-$36.5M |
FOLD, KRYS, AKRO, REPL, FATE
|
13F-HR |
2/14/2023, 04:18 PM |
Q3 2022 |
70 |
$2.58B |
+$313M |
-$485M |
-$171M |
FATE, FOLD, KRYS, ARGX, PLRX
|
13F-HR |
11/14/2022, 04:03 PM |
Q2 2022 |
71 |
$2.62B |
+$275M |
-$149M |
+$125M |
FATE, FOLD, SGEN, ARGX, KRYS
|
13F-HR |
8/15/2022, 05:22 PM |
Q1 2022 |
70 |
$3.19B |
+$179M |
-$180M |
-$1.25M |
FATE, FOLD, ARGX, LIVN, KRYS
|
13F-HR |
5/16/2022, 04:13 PM |
Q4 2021 |
71 |
$4.4B |
+$449M |
-$735M |
-$286M |
FATE, FOLD, SNCE, ARGX, LIVN
|
13F-HR |
2/14/2022, 05:07 PM |
Q3 2021 |
75 |
$5.73B |
+$516M |
-$714M |
-$198M |
FATE, ALLK, IGMS, ARGX, ADCT
|
13F-HR |
11/15/2021, 04:16 PM |
Q2 2021 |
86 |
$6.76B |
+$476M |
-$812M |
-$336M |
FATE, IGMS, BEAM, ARGX, FOLD
|
13F-HR |
8/16/2021, 05:00 PM |
Q1 2021 |
86 |
$7.1B |
+$1.13B |
-$1.4B |
-$261M |
FATE, ALLK, IGMS, ARGX, FOLD
|
13F-HR |
5/17/2021, 04:05 PM |
Q4 2020 |
87 |
$8.25B |
+$1.61B |
-$739M |
+$872M |
FATE, FOLD, ALLK, BEAM, IGMS
|
13F-HR |
2/16/2021, 04:06 PM |
Q3 2020 |
81 |
$5.45B |
+$1.15B |
-$1.07B |
+$83.4M |
FATE, FOLD, IMMU, ARGX, IGMS
|
13F-HR |
11/16/2020, 04:09 PM |
Q2 2020 |
80 |
$5.42B |
+$1.48B |
-$724M |
+$755M |
FATE, FOLD, DCPH, ADCT, ARGX
|
13F-HR |
8/14/2020, 04:16 PM |
Q1 2020 |
69 |
$3.57B |
+$674M |
-$674M |
+$230K |
FATE, FOLD, DCPH, BIIB, IGMS
|
13F-HR |
5/15/2020, 04:04 PM |
Q4 2019 |
64 |
$4.18B |
+$1.11B |
-$854M |
+$260M |
DCPH, ALLK, FOLD, FATE, EPZM
|
13F-HR |
2/14/2020, 04:10 PM |
Q3 2019 |
74 |
$2.99B |
+$709M |
-$838M |
-$129M |
ALLK, FOLD, FATE, DCPH, ALDR
|
13F-HR |
11/14/2019, 04:11 PM |
Q2 2019 |
80 |
$3.53B |
+$596M |
-$639M |
-$43.3M |
ARRY, FOLD, FATE, ARGX, QURE
|
13F-HR |
8/14/2019, 04:04 PM |
Q1 2019 |
82 |
$3.42B |
+$662M |
-$300M |
+$362M |
ARRY, FOLD, FATE, ATRA, ARGX
|
Restatement |
5/17/2019, 08:56 PM |
Q4 2018 |
78 |
$2.49B |
+$373M |
-$590M |
-$217M |
ARRY, ATRA, FATE, XNCR, WVE
|
Restatement |
5/16/2019, 03:34 PM |
Q3 2018 |
83 |
$3.25B |
+$699M |
-$490M |
+$209M |
ARRY, ATRA, FATE, RGNX, XNCR
|
Restatement |
5/16/2019, 03:34 PM |
Q2 2018 |
81 |
$2.94B |
+$705M |
-$593M |
+$112M |
ARRY, FOLD, ATRA, IMGN, XNCR
|
13F-HR |
8/14/2018, 04:32 PM |
Q1 2018 |
64 |
$2.59B |
+$592M |
-$522M |
+$69.6M |
ARRY, ATRA, FOLD, IMGN, XNCR
|
13F-HR |
5/15/2018, 04:30 PM |
Q4 2017 |
1 |
$6.6M |
$0 |
$0 |
|
LIFE
|
New Holdings |
3/8/2018, 04:01 PM |
Q4 2017 |
70 |
$2.3B |
+$678M |
-$391M |
+$288M |
ARRY, FOLD, PBYI, CLVSQ, WVE
|
13F-HR |
2/14/2018, 05:03 PM |
Q3 2017 |
65 |
$2.03B |
+$628M |
-$467M |
+$161M |
ARRY, FOLD, PBYI, SGEN, CLVSQ
|
13F-HR |
11/14/2017, 04:23 PM |
Q2 2017 |
62 |
$1.62B |
+$374M |
-$424M |
-$50.1M |
ARRY, FOLD, PEN, PBYI, CLVSQ
|
13F-HR |
8/14/2017, 05:39 PM |
Q1 2017 |
60 |
$1.54B |
+$489M |
-$303M |
+$186M |
ARRY, PEN, FOLD, PBYI, CLVSQ
|
13F-HR |
5/15/2017, 04:41 PM |
Q4 2016 |
50 |
$1.16B |
+$246M |
-$231M |
+$15.5M |
ARRY, SGEN, CLVSQ, PEN, FOLD
|
13F-HR |
2/14/2017, 04:40 PM |
Q3 2016 |
51 |
$1.26B |
+$383M |
-$415M |
-$31.7M |
ARRY, SGEN, FOLD, CLVSQ, GWPH
|
13F-HR |
11/14/2016, 06:26 PM |
Q2 2016 |
54 |
$1.05B |
+$260M |
-$255M |
+$5.19M |
ARRY, FOLD, MDVN, SGEN, ATRA
|
13F-HR |
8/15/2016, 06:47 PM |
Q1 2016 |
46 |
$966M |
+$246M |
-$342M |
-$95.5M |
FOLD, MDVN, CLVSQ, PEN, ARRY
|
13F-HR |
5/16/2016, 05:22 PM |
Q4 2015 |
56 |
$1.3B |
+$365M |
-$380M |
-$15.3M |
FOLD, MDVN, PEN, ARRY, ITCI
|
13F-HR |
2/16/2016, 04:53 PM |
Q3 2015 |
58 |
$1.32B |
+$735M |
-$521M |
+$214M |
FOLD, CLVSQ, ARRY, MDVN, INCY
|
Restatement |
11/17/2015, 03:23 PM |
Q2 2015 |
55 |
$1.22B |
+$394M |
-$366M |
+$27.5M |
ARRY, FOLD, VRX, CLVSQ, TEVA
|
13F-HR |
8/14/2015, 04:27 PM |
Q1 2015 |
54 |
$1.11B |
+$435M |
-$346M |
+$88.3M |
ARRY, CLVSQ, FOLD, VRX, TEVA
|
13F-HR |
5/15/2015, 07:11 PM |
Q4 2014 |
54 |
$918M |
+$210M |
-$257M |
-$47.3M |
FOLD, ARRY, VRX, CMRX, RAD
|
13F-HR |
2/17/2015, 07:28 PM |
Q3 2014 |
52 |
$812M |
+$314M |
-$345M |
-$30.9M |
VRX, B108PS, CLVSQ, CELG, FOLD
|
13F-HR |
11/14/2014, 04:29 PM |
Q2 2014 |
47 |
$822M |
+$334M |
-$328M |
+$5.83M |
B108PS, MDT, ARRY, UHS, HCA
|
13F-HR |
8/14/2014, 06:52 PM |
Q1 2014 |
55 |
$838M |
+$363M |
-$443M |
-$80.4M |
B108PS, HCA, A, VRX, CLVSQ
|
Restatement |
8/19/2014, 02:09 PM |
Q4 2013 |
55 |
$796M |
$0 |
$0 |
|
GILD, CLVSQ, ZBH, CELG, AZN
|
13F-HR |
2/14/2014, 05:16 PM |